Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma

被引:105
作者
Lewis, JJ
Leung, D
Casper, ES
Woodruff, J
Hajdu, SI
Brennan, MF
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[4] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
D O I
10.1001/archsurg.134.2.190
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: The majority of survival studies in patients with extremity soft tissue sarcoma have focused on early recurrence and mortality. There are few data addressing long-term follow-up and survival. Objective: To analyze survival and recurrence in patients with extremity soft tissue sarcoma who survive for more than 5 years. Methods: Patients who underwent treatment for primary tumors (July 1982 to July 1994) and were followed up for more than 5 years were the subject of study. Disease-specific and disease-free survival were determined actuarially. Significance was evaluated using log-rank testing for univariate analysis and Cox model stepwise regression for multivariate analysis. Results: A total of 495 patients with primary extremity rumors were treated before July 1989 and eligible for 5-year follow-up. Of these, 282 have been followed up for more than 5 years (median follow-up, 84.4 months). Actuarial disease-specific survival of patients who survive for longer than 5 years was 79% +/- 7% (+/-SEM) at 10 years, and of those who were metastasis free at 5 years was 91% +/- 4% at 10 years. On univariate analysis, post-5-year disease-specific survival was influenced by positive microscopic margin and initial tumor size of 5 cm or greater. On multivariate analysis, post-5-year disease-specific survival was influenced only by positive margins. Conclusions: Based on these analyses, 21% of patients with primary extremity sarcoma who survive for 5 years will die of disease within 5 years. Even of those who are metastasis free at 5 years, 9% will die of disease within 5 years. In contrast to early mortality, tumor grade has no influence on post-5-year prognosis. Patients with positive microscopic margins are at risk for post-5-year disease-specific mortality and therefore require longterm follow-up and consideration For investigational therapy.
引用
收藏
页码:190 / 194
页数:5
相关论文
共 21 条
[1]   THE ROLE OF MULTIMODALITY THERAPY IN SOFT-TISSUE SARCOMA [J].
BRENNAN, MF ;
CASPER, ES ;
HARRISON, LB ;
SHIU, MH ;
GAYNOR, J ;
HAJDU, SI .
ANNALS OF SURGERY, 1991, 214 (03) :328-338
[2]   PROGNOSTIC FACTORS FOR LOCAL RECURRENCE AND SURVIVAL IN PATIENTS WITH LOCALIZED EXTREMITY SOFT-TISSUE SARCOMA [J].
COLLIN, CF ;
FRIEDRICH, C ;
GODBOLD, J ;
HAJDU, S ;
BRENNAN, MF .
SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (01) :30-37
[3]   THE EFFECT OF LOCAL RECURRENCE ON SURVIVAL-TIME IN ADULT HIGH-GRADE SOFT-TISSUE SARCOMAS [J].
EMRICH, LJ ;
RUKA, W ;
DRISCOLL, DL ;
KARAKOUSIS, CP .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1989, 42 (02) :105-110
[4]   REFINEMENT OF CLINICOPATHOLOGICAL STAGING FOR LOCALIZED SOFT-TISSUE SARCOMA OF THE EXTREMITY - A STUDY OF 423 ADULTS [J].
GAYNOR, JJ ;
TAN, CC ;
CASPER, ES ;
COLLIN, CF ;
FRIEDRICH, C ;
SHIU, M ;
HAJDU, SI ;
BRENNAN, MF .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (08) :1317-1329
[5]  
GEER RJ, 1992, ARCH SURG-CHICAGO, V127, P1285
[6]  
GUSTAFSON P, 1991, CANCER, V67, P2083, DOI 10.1002/1097-0142(19910415)67:8<2083::AID-CNCR2820670813>3.0.CO
[7]  
2-5
[8]   METASTASIS-FREE SURVIVAL AFTER LOCAL RECURRENCE OF SOFT-TISSUE SARCOMA [J].
GUSTAFSON, P ;
DREINHOFER, KE ;
RYDHOLM, A .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1993, 75 (04) :658-660
[9]   THE ROLE OF THE PATHOLOGIST IN THE MANAGEMENT OF SOFT-TISSUE SARCOMAS [J].
HAJDU, SI ;
SHIU, MH ;
BRENNAN, MF .
WORLD JOURNAL OF SURGERY, 1988, 12 (03) :326-331
[10]  
HERBERT SH, 1993, CANCER, V72, P1230, DOI 10.1002/1097-0142(19930815)72:4<1230::AID-CNCR2820720416>3.0.CO